Loading
Life sciences · Journal article
World Journal of Surgical Oncology · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Conversion surgery has emerged as a treatment strategy for selected patients with initially unresectable or metastatic gastric cancer who achieve a favourable response to systemic therapy. Advances in chemotherapy, immunotherapy, and targeted therapies have increased response rates and expanded the population of potential surgical candidates. However, clinical response does not reliably reflect pathological eradication of disease, particularly in patients with peritoneal metastases. This review presents a clinically oriented, response-driven framework for conversion surgery, emphasizing tumour biology rather than baseline staging. We discuss current evidence, limitations of response assessment, and the impact of modern systemic therapies. Conversion surgery should be considered an opportunity emerging in selected responders rather than a predefined treatment strategy.